ClinicalTrials.gg
RecruitingNCT05974904Updated Feb 12, 2025

Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

An observational study in Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis and Liver Fibrosis, sponsored by Chongqing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Chongqing Medical University · Observational

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
7,000
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Fatty Liver with a site in China — 31 open to participants now, 35 under way, 2 of them phase 3. Fatty Liver · China.

Planned enrollment
3rd of 27
7,000 · median 400
Started
2023
with 2 others
Observational
27 of 64
12 open now
Primary completion
2026-12
later than 13 of 34 live
Registered
27th of 64
by date

Among the 64 studies in Fatty Liver with a site in China, this one is the 3rd largest by planned enrollment of the 27 observational ones that give a count, is one of 3 that started in 2023, is one of 27 observational ones, reaches primary completion later than 13 of the 34 other live ones, and was the 27th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

31 of the 64 studies in Fatty Liver with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Fatty Liver with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD).

The main question[s] it aims to answer are:

[question 1] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? [question 2] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?

Read the detailed description

Background Inflammation is related to the occurrence and development of fatty liver. Our research aimed to investigate the link between an inflammatory indicator, high-sensitivity C-reactive protein to albumin ratio (hsCAR), and metabolic dysfunction-associated fatty liver disease (MAFLD).

Methods Ultrasonic indices were used to evaluate the severity of liver steatosis and fibrosis of participants from the NHANES database, respectively. The relationship between hsCAR and MAFLD was explored using multivariate logistic regression analysis, restricted cubic splines (RCS) as well as threshold analysis. Finally, subgroup analyses were performed using the same methodology.

03

Conditions studied

  • Metabolic Dysfunction-associated Fatty Liver Disease
  • Hepatic Steatosis
  • Liver Fibrosis

Keywords

  • high-sensitivity C-reactive protein to albumin ratio
  • metabolic dysfunction-associated fatty liver disease
  • National Health and Nutrition Examination Survey
  • control attenuation parameter
  • liver stiffness measurement
  • inflammation
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

They all come from the National Health and Nutrition Examination Survey, which is a database that contains information about demographics, dietary, examination, laboratory and questionnaire of the American population obtained through sophisticated sampling strategies.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Total participants from NHANES 2017-2020
  • Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus.

    1. Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) ≥ 6.5% (48 mmol/mol); (3) fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol/L (200 mg/dL).
    2. Overweight or obesity: defined as ≥25 kg/m2 in Caucasians or BMI≥23 kg/m2 in Asians
    3. If presence of at least two metabolic risk abnormalities:

      • Waist circumference≥102/88 cm in Caucasian men and women (or≥90/80 cm in Asian men and women)
      • Blood pressure≥130/85 mmHg or specific drug treatment
      • Plasma triglycerides≥150 mg/dl (≥1.70 mmol/L) or specific drug treatment
      • Plasma HDL-cholesterol \<40 mg/dl (\<1.0 mmol/L) for men and \<50 mg/dl (\<1.3 mmol/L) for women or specific drug treatment
      • Prediabetes (i.e., fasting glucose levels 100 to 125 mg/dl [5.6 to 6.9 mmol/L], or 2-hour post-load glucose levels 140 to 199 mg/dl [7.8 to 11.0 mmol] or HbA1c 5.7% to 6.4% [39 to 47 mmol/mol])
      • Homeostasis model assessment of insulin resistance score≥2.5
      • Plasma high-sensitivity C-reactive protein level >2 mg/L

Exclusion criteria

Exclusion Criteria:

  • Liver ultrasound data not available
  • participants without complete clinical data
  • participants under 18 years old
  • participants with cancer.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
7,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Non-MAFLD group

    controlled attenuation parameter\<274 dB/m

  • MAFLD group

    controlled attenuation parameter ≥ 274 dB/m

    Other: high-sensitivity C-reactive protein to albumin ratio

  • Non-fibrosis group

    liver stiffness measurement \< 8.2 kPa

  • Fibrosis group

    liver stiffness measurement ≥ 8.2 kPa

    Other: high-sensitivity C-reactive protein to albumin ratio

Interventions

  • Otherhigh-sensitivity C-reactive protein to albumin ratio

    High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.

06

What researchers measure

Primary outcomes

  1. Controlled attenuation parameter

    Controlled attenuation parameter is an ultrasound indicator measured by FibroScan to evaluate the degree of liver steatosis

    Time frame: at baseline

Secondary outcomes

  1. Liver stiffness measurement

    Liver stiffness measurement is an ultrasound indicator measured by FibroScan to evaluate the degree of liver stiffness

    Time frame: at baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Jarvinen H, Fan JG, Gronbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8. PubMed 32278004 ↗
  • Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042. Epub 2019 Jan 25. PubMed 30689971 ↗
  • Karimi A, Shobeiri P, Kulasinghe A, Rezaei N. Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis. Front Immunol. 2021 Oct 22;12:741061. doi: 10.3389/fimmu.2021.741061. eCollection 2021. PubMed 34745112 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 3, 2023
StartActual
Jul 18, 2023
Primary completionEst.
Dec 28, 2026
CompletionEst.
Dec 28, 2026
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05974904
Lead sponsor
Chongqing Medical University
Responsible party
Tingqiu Wang (Principal Investigator, Chongqing Medical University) — Principal investigator
First posted
Aug 3, 2023
Start date
Jul 18, 2023
Primary completion
Dec 28, 2026 (estimated)
Completion
Dec 28, 2026 (estimated)
Last update
Feb 12, 2025

Study contacts

Tingqiu Wang, Bachelor
Contact
w857683014@163.com
+8617815370539
Zhigang Luo, Master
Contact
306395@hospital.cqmu.edu.cn
+8618989126596
Tingqiu Wang, Bachelor
study director · The Second Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion